|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
CALCIUM CHANNEL BLOCKERS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
INCREASED RISK OF CARDIOTOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|